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1. Introduction  
Mitochondria are dynamic, semi-autonomous organelles that play a diverse role in cellular 
physiopathology, being involved in bioenergetics, ROS generation/signaling and redox 
balance, β-oxidation of free fatty acids, Ca2+ homeostasis, thermogenesis, and essential 
anabolic pathways (fatty acids, cholesterol, urea, haem and bile acids). They contain their own, 
mitochondrial DNA (mtDNA) which is one of the main points in favor of the hypothesis of the 
endosymbiotic origin of these organelles (Lang et al., 1999). The human mitochondrial 
genome, a 16.5 kb circular DNA consisting of a heavy and a light chain, contains 37 genes, 13 
of which encode proteins involved in the mitochondrial electron transport chain (ETC), 22 of 
which encode transfer RNA and the remaining 2 genes encode ribosomal RNA. A mammalian 
somatic cell contains between 1000 and 10000 copies of mtDNA arranged in covalently closed 
circular molecules. There are considerable physiological variations in the mtDNA content in 
any given human tissue, however the mechanism of these modulations and their clinical 
relevance are still not clear. Like bacterial chromosomal DNA, mtDNA is organized in DNA-
protein structures called nucleoids. Several proteins seem to be involved in the maintenance of 
these structures. The most widely studied is Transcription Factor A (TFAM) which has a clear 
structural role and is necessary for nucleoid stabilization. 
2. Replication of mtDNA 
The replication of mtDNA is wholly dependent on the nucleus. The minimal mtDNA 
replication apparatus consists of DNA polymerase γ (Pol γ) and two replication factors: 
mitochondrial single-stranded DNA binding protein (SSB) and the Twinkle helicase. Pol γ is 
the only known DNA polymerase present in mammalian mitochondria (there are 16 DNA 
polymerases in the eukaryotic cell) and carries out both DNA replication and DNA repairing 
function (Bebenek & Kunkel, 2004; Sweasy et al., 2006). The presence of a specific 
mitochondrial DNA polymerase was suggested in the late 1960s with the discovery of a 
polymerase in mitochondrial fractions that exhibited distinct characteristics from known 
mammalian DNA polymerases (Kalf et al., 1968). Several years later, a novel human 
polymerase was identified in HeLa cells that could utilize DNA/RNA primer templates 
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(Fridlender et al., 1972) which was eventually identified as mitochondrial DNA polymerase 
(Bolden et al., 1977). The holoenzyme of Pol γ consists of a catalytic subunit encoded by POLG 
(located at the chromosomal locus 15q25) and a dimeric form of an accessory subunit p55 
encoded by POLG2 (located at the chromosomal locus 17q24.1), which all together form the 
Pol γ holoenzyme (Yakubovskaya et al., 2006). Pol γ is a 140kDa enzyme that possesses DNA 
polymerase but also additional intrinsic activities such as 3´-5´ proofreading exonuclease 
activity and 5´ deoxyribonucleic phosphate lyase activity, which are responsible for base 
excision repair (Graziewicz et al., 2006) (Fig.1). Initial pre-steady state kinetic analyses of Pol γ 
demonstrated that the catalytic subunit of this enzyme alone was somewhat inefficient, with 
relatively weak binding to DNA (39nM) and a slow maximum rate of polymerization (3.5s-1). 
Processivity of the enzyme was estimated to be about 50-100 nucleotides (Graves et al., 1998; 
Longley et al., 1998). Thus, it became clear that the catalytic subunit was insufficient for 
successful DNA replication. An accessory subunit was purified and described as a 55kDa 
protein required for tight DNA binding and processing DNA synthesis (Lim et al., 1999). 
Kinetic analysis showed that the accessory and the catalytic subunit bind with a Kd of 35nM 
and that this association enhances enzyme processivity from several hundreds to thousands of 
nucleotides. This enhancement was not linked to a significant decrease in the dissociation rate 
of the holoenzyme from the primer/template (Johnson et al., 2000). However, the accessory 
subunit provides a 3.5-fold increase in DNA binding affinity and a 6-fold decrease in Kd for 
dATP incorporation. The accessory subunit has also been suggested to play a role in primer 
recognition (Fan et al., 1999) and its ability to bind nucleic acids, particularly dsDNA, has also 
been demonstrated, which is very uncommon for processing factors. This feature points to a 
function of the accessory unit not directly related with mtDNA synthesis; namely it has been 
suggested to have a role in maintenance of the mitochondrial genome, specifically by 
organization of mtDNA in nucleoids (Di Re et al., 2009). Pol γ has high base substitution 
fidelity due to high nucleotide selectivity and 3´-5´ exonucleolytic proofreading. It is 
particularly efficient in base incorporation in short repetitive sequences in which a 
missinsertion has been estimated to occur only once in every 500000 nucleotides (Longley et 
al., 2001). However, for copying homopolymeric sequences longer than 4 nucleotides, Pol γ has 
lower frameshift fidelity, which can lead to replication errors and frameshift mutations in 
mtDNA. Importantly, Pol γ contains an intrinsic 3´-5´ exonuclease activity that contributes to 
its replication fidelity. 
The exonuclease activity is also efficient in repairing buried mismatches. Several additional 
factors have also been reported to contribute to mtDNA replication and/or repair, such as 
mitochondrial DNA-directed RNA polymerase (POLRMT), RNA-DNA hybrid-specific 
RNase, Topoisomerase I and IIIα, 5´-3´ Flap endonuclease, 5´-3´ exonuclease, uracil DNA 
glycosylase and 8-oxo-dG glycosylase, among others (Table 1)(Copeland, 2010). 
Pol γ has three main roles related to disease. 
- Synthesis and repair, the origin of most spontaneous mtDNA mutations are believed to 
be due to errors produced by Pol γ. Comparison of the mutation spectrum from in vivo 
sources with DNA copied in vitro by purified human Pol γ has revealed that over 85% of 
the in vivo mutations can be recapitulated in vitro (Zheng et al., 2006). 
- Inherited mutations in POLG- more than 150 disease-associated mutations have been 
described in this gene (Copeland, 2010). 
- Mitochondrial toxicity induced by NRTI drugs- Pol γ is the only DNA polymerase that 
is sensitive to the nucleoside analogues used for HIV treatment (Lim et al., 2003; Lewis 
et al., 2006). 
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Fig. 1. Crystal structure of the Pol γ  holoenzyme. Canonical right hand organization of the 
polymerase domain: fingers (orange), palm (green) and thumb (blue). Additional domains: 
mitochondrial localization sequence (yellow), exonuclease (red) and spacer (purple). 
Dimeric accessory subunit: proximal (cyan) and distal (light cyan) monomers (From Bailey 
& Anderson, 2010). 
2.1 Mechanism of mtDNA replication and repair 
Although mtDNA replication was identified as far back as 1972, it was only in the last 
decade that researchers began to understand its complex mechanism. Basically, two models 
have been proposed for replication of the mitochondrial genome: the strand-displacement 
theory and the strand-coupled theory. The strand-displacement theory suggests that 
replication is performed in one direction in a continuous manner without requiring the 
processing of Okazaki fragments on the displaced strand (Clayton, 1982). Copying of the 
mitochondrial genome begins at the origin of replication of the heavy strand DNA in the 
non-coding D-loop region of the mitochondrial genome, displacing the light chain until 
progressing two thirds of the way around the circular DNA. Synthesis of the light chain 
then begins after the formation of a stem-loop structure of the displaced heavy chain which 
forms the replication origin of the light strand DNA (Shadel et al., 1997). The strand-coupled 
model suggests that the synthesis occurs bidirectionally from multiple sites of initiation in a 
zone near the origin of the heavy chain replication (Holt et al., 2000; Bowmaker et al., 2003). 
Of note, there is a high prevalence of ribonucleotides in the lagging strand during mtDNA 
replication, which has more recently led to an alternative view of the strand-displacement 
theory termed RITOLS (RNA incorporated throughout the lagging strand) replication 
(Yasukawa et al., 2006; Holt, 2009). In this process, large patches of RNA protect the 
displaced strand during one-directional DNA synthesis. Short RNA templates are used as 
primers to complete replication of the lagging strand. This phenomenon may explain the lag 
between synthesis of the heavy and light chains of mtDNA. 
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Function Gene Protein 
Size 
(kDa)
Chromosome 
locus 
Core 
replication 
POLG DNA polymerase γ 140 15q25 
POLG2 
DNA polymerase γ accessory 
subunit 
55 17q23-24 
SSB 
Single stranded DNA binding 
protein  
15 7q34 
PEO1 
(Twinkle) 
Helicase 77 10q24 
Replication 
and repair 
DNA ligase III Ligase 96 17q11.2-12 
RNase H1 RNA-DNA hybrid specific RNase 32 19p13.2 
Topo I Topoisomerase I 67 8q24.3 
Topo IIIα Topoisomerase IIIα 112 17p12-11.2 
Fen-1 5´-3´Flap endonuclease 43 11q12 
DNA2 
5´-3´DNA/RNA 
endonuclease/exonuclease 
130 10q21.3-q22.1 
ExoG 5´-3´exonuclease 41 3p21.3 
DNA repair 
UDG Uracil DNA glycosylase 27.5 12q23-q24.1 
OGG1 8-oxo-dG glycosylase 38 3p26.2 
NTH1 Thymine glycol glycosylase 34 16p13.3 
MUTYH glycosylase 60 1p34.3-p32.1 
NEIL1 Fapy glycosylase 44 15q4.2 
APE1 Ap endonuclease  35 14q11.2-q12 
APE2 Ap endonuclease 57 Xp11.22 
Table 1. Gene products required for mtDNA replication and repair. Ap (apurinic, 
apyrimidinic); Fapy (2,6-diamino-4-hydroxy-formamido-pyrimidine) (Modified from 
Copeland, 2010). 
mtDNA repair is limited to base excision repair (BER), for which the mitochondrion is 
equipped with several glycosylases that recognize base damage. Mitochondrial excision 
base repair can be performed via two pathways: single-nucleotide-BER (SN-BER) and long-
patch BER (LP-BER) (Copeland & Longley, 2008). In both repair pathways, a damaged base 
is recognized and cleaved by a specific glycosylase, leaving an abasic site that is further 
cleaved on the 5´ end by AP nuclease to generate a nick with a 5´ deoxyribose phosphate 
(dRP) flap. During SN-BER, Pol γ fills the gap and cleaves the 5´dRP moiety prior to ligation. 
LP-BER seems to need the activity of additional proteins such as 5´-3´Flap endonuclease 
(FEN-1) (Liu et al., 2008) and 5´-3´DNA/RNA endonuclease/exonuclease (DNA2) (Zheng et 
al., 2008).    
Current efforts are focused not only on elucidating the process of replication but particularly 
on identifying the factors involved in mtDNA repair and maintenance. This special interest 
is due to the observation that mtDNA depletion and/or mutation underlies a constantly 
growing list of human pathologies (Wanrooij & Falkenberg, 2010). 
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3. Inherited mitochondrial diseases which involve impaired DNA replication 
Mitochondrial depletion syndrome (MDS) is a heterogeneous group of inherited disorders, 
characterized by a decreased amount of mtDNA in a specific tissue. The most severely 
affected organs include the brain, muscle and liver. This syndrome includes a wide 
spectrum of clinical disorders ranging from well-known diseases such as progressive 
external ophthalmoplegia (PEO) to rare tricarboxylic acid (TCA) cycle abnormalities. 
Typically, MDS are devastating and usually lethal diseases of infancy or early childhood 
and show autosomal recessive inheritance (Suomalainen & Isohanni, 2010). Since 1999, a 
dozen genes linked to MDS and related disorders have been described including mutations 
in the essential genes of mtDNA replication machinery: POLG, POLG2 and TWINKLE. POLG 
is the most common of the genes that cause MDS and is believed to be the cause of 25% of 
described mitochondriopathies. Nearly 150 pathogenic mutations have been found in POLG 
(Copeland, 2010) which result in highly heterogenous disorders, such as PEO, Parkinson´s 
disease, Alpers syndrome, sensory ataxic neuropathy, mitochondrial neurogastrointestinal 
encephalomyopathy, dysarthria, Charcot-Marie-Tooth syndrome and ophthalmoparesis. In 
addition, mutations in several nuclear genes encoding enzymes involved in the 
mitochondrial nucleotide metabolism can cause depletions of mtDNA, resulting in 
mitochondrial syndromes. These include mitochondrial thymidine kinase (TK2), a 
pyrimidine nucleoside kinase essential to post-mitotic cells for phosphorylation of 
pyrimidine nucleosides, deoxyguanosine kinase (DGUOK), an enzyme necessary for 
mitochondrial purine nucleoside salvage pathways, adenine nucleotide translocator 
(ANT1), and mitochondrial deoxynucleotide carrier (DNC) (Suomalainen & Isohanni, 2010). 
Indeed, the fact that many genes involved in nucleotide salvage pathways and nucleotide 
transport are responsible for mitochondrial diseases suggests that imbalanced nucleotide 
pools are detrimental to mtDNA replication. The inherited mitochondrial diseases involving 
mtDNA replication are characterized by a long range of overlapping and progressing 
clinical symptoms, most commonly lactic acidosis, muscle weakness and myopathy which 
can lead to ataxia, polyneuropathy with epilepsy, cognitive delay and sensory impairment 
(ophthalmoplegia, deafness) as well as liver and gastrointestinal alterations (dysmotility) 
(Copleand, 2008; Copeland, 2010). According to the manifestations of the disease, MDS can 
be divided into three categories: myopathic, encephalomyopathic and hepatocerebral. To 
illustrate these effects, two inherited POLG-originated diseases are described. PEO, a 
mitochondrial disorder characterized by mtDNA depletions and/or accumulation of 
mutated mtDNA, has a late onset (between 18 and 40 years of age) and results in 
progressive weakening of the external eye muscles, leading to blepharoptosis and 
ophthalmoparesis (Copeland, 2008). PEO patients also manifest skeletal muscle weakness 
and wasting accompanied by exercise intolerance. This disease is also associated with 
specific neurologic syndromes such as familial forms of spastic paraplegia, spinocerebellar 
disorders, and sensorimotor peripheral neuropathy. The variants of this disorder involve 
both autosomal dominant (adPEO) and recessive (arPEO) forms, as both the nuclear and the 
mitochondrial genome are implicated in this pathogenesis. Importantly, several mutations 
in POLG, the first of which was described in 2001, are involved in the development of PEO. 
Alpers syndrome is another disease caused by mutations in POLG (Copeland, 2008). This is 
a rare but very severe and usually lethal autosomal recessive MDS disease that appears 
within the first few years of life. Patients exhibit progressive spastic quadri-paresis, 
progressive cerebral degeneration leading to mental deterioration, cortical blindness, 
deafness and liver failure. 
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4. mtDNA replication and NRTI 
The most widely studied class of drugs that inhibit mtDNA replication, thus generating 
drug-related toxicities, are the nucleoside analog reverse transcriptase inhibitors (NRTI) 
(Fig.2). This was the first family of drugs approved by FDA for treatment of HIV infection 
(zidovudine, 1987). The combined antiretroviral approach currently employed in HIV 
therapeutics was introduced in 1996 and is known as Highly Active Antiretroviral Therapy 
(HAART) or Combination Antiretroviral Therapy (cART). It involves the use of one or two 
NRTI and one Non-Nucleoside Analogue Reverse Inhibitor (NNRTI) or one protease 
inhibitor (Zolopa, 2010). In this way, NRTI constitute the cornerstone of current HIV 
therapy. They are administered as prodrugs that must be transported into the cell and 
phopshorylated to the metabolically active triphosphate in order to exert their therapeutic 
effect. These drugs are pharmacological analogues of native nucleosides that can be  
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Fig. 2. The interference of NRTI drugs with the life cycle of HIV. 
Reverse Transcriptase Inhibitors are a group of antiretroviral drugs which inhibit the viral 
reverse transcriptase, a crucial enzyme of the HIV life cycle. This enzyme reverse-transcribes 
the viral RNA genome into DNA, which is then integrated into the host genome and 
replicated along with it. This drug group comprises nucleoside analogues (NRTI) and non-
nucleoside analogues (NNRTI). NRTI are administered as prodrugs and act as competitive 
inhibitors whereas NNRTI which do not require intracellular activation exert a non-
competitive inhibitory action by acting at an allosteric, non-substrate binding site and 
thereby inducing a conformational change which impairs the enzyme’s catalytic activity. 
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incorporated into proviral DNA during DNA replication by reverse transcriptase. Because 
they lack the 3´-OH group, their incorporation results in the termination of viral DNA 
replication. However, the triphosphate forms of the analogues have also been shown to be 
substrates for Pol γ and can also provoke termination of the DNA chain during mtDNA 
replication, an effect which can alter mitochondrial function. It has been postulated that 
NRTI inhibits Pol γ through several mechanisms or a combination of them: 1) termination of 
the mtDNA chain due to incorporation of NRTI in the growing strand without the 3´-OH 
group; 2) direct competitive inhibition of Pol γ without incorporation in the nascent DNA 
chain, as they compete with natural nucleotides for such incorporation; 3) alteration of  Pol γ 
synthesis fidelity -induction of errors during mtDNA replication by inhibition of the 
exonucleolytic proof-reading function of Pol γ; 4) decrease in mtDNA reparatory 
exonuclease activity as NRTI resists exonucleolytic removal. Additional effects on mtDNA 
synthesis have also been suggested. Regardless of the mechanism by which mtDNA 
replication is compromised, it ultimately interferes with the synthesis of essential proteins of 
the mitochondrial ETC (Chiao et al., 2009). 
The “Pol γ hypothesis” holds that NRTI treatment disrupts the OxPhos process thereby 
generating an energy defect and triggering subsequent alterations in the mitochondrial 
function such as increase in ROS production, reduced ATP synthesis, electron leakage, 
changes in the mitochondrial membrane potential and ROS generation, alterations which 
lead to further cellular damage (Fig.3),(Kohler & Lewis, 2007). Clinical experience with 
NRTI-including therapy has revealed the appearance of several side effects ranging from 
hyperlactatemia and lactic acidosis to lipodystrophy, myopathy, peripheral neuropathy, 
bone marrow suppression, insulin resistance and diabetes, as well as hepatosteatosis and 
pancreatitis, some of which develop into life-threatening condition (Kakuda, 2000). The first 
report of NRTI-induced mitochondrial effects, described in 1990, was myopathy in patients 
treated with zidovudine, who exhibited ragged red muscle fibers and reduced mtDNA 
content (Dalakas et al., 1990). Cardiomyopathy and bone marrow suppression were also 
described.  
Kinetic in vitro studies have reported that dideoxynucleotides can be substrates for Pol γ  
nearly as efficiently as natural deoxynucleotides and thus the proposed hierarchy of 
mitochondrial toxicity for the approved NRTI is: zalcitabine >didanosine >stavudine >> 
lamivudine >tenofovir >zidovudine >abacavir (Lim & Copeland, 2001). Once incorporated 
into DNA, terminal NRTI can be removed by the intrinsic exonuclease activity of Pol γ, 
however this action is quite inefficient particularly in the case of dideoxynucleotides. For, 
example, zidovudine is unlikely to be incorporated into DNA by Pol γ, but once 
incorporated its removal is very inefficient which may explain the strong zidovudine-
induced mtDNA depletion observed in vitro (Lim et al., 2003).  
In contrast, removal of 3´- terminal lamivudine residues is 50% as efficient as natural 3´-
termini. This, together with the lower degree of lamivudine incorporation in the mtDNA 
chain, predicts reduced toxicity for this analogue, a finding which is supported by in vivo 
observations. Pol γ discrimination against specific NRTI drugs, as illustrated in the 
examples, is considered the basis of the mitochondrial toxicity induced by these compounds 
and is a major rationale in the design of new antiretroviral nucleoside analogs.  
Three aminoacid residues in human Pol γ (Tyr951, Tyr955 and Glu895) are thought to 
account for the selection of dNTPs and, therefore, NRTI (Lim et al., 2003). For example, a 
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Fig. 3. The effect of NRTI drugs on Pol γ and its consequences for mitochondrial function. 
NRTI drugs are prodrugs which are phosphorylated intracellularly and the generated 
triphosphate form inhibits Pol γ in a competitive fashion. This undermines mtDNA 
synthesis with a consequent depletion of the mtDNA-encoded subunits of the mitochondrial 
electron transport chain. Such an effect leads to impairment of the mitochondrial function 
manifested as compromised oxidative phosphorylation, a reduction in mitochondrial 
membrane potential and induction of oxidative stress. 
single tyrosine in motif B of human Pol γ, Tyr951, has been shown to cause 
dideoxynucleoside and stavudine sensitivity. Substitution of this Tyr residue with 
phenylalanine reduces the inhibition by dideoxynucleotides or stavudine by several 
thousand-fold with only minor effects on the overall function of Pol γ (Lim et al., 2003). It 
was hypothesized that the phenolic hydroxyl group of the tyrosine residue could substitute 
the missing 3´-OH of the bound ddNTP, thus allowing its efficient incorporation. Tyr955 
and Glu895 seem to interact with the rigid sugar rings of stavudine and abacavir. 
Interestingly, discrimination against zidovudine does not seem to be related to any of these 
aminoacid residues at the active site of Pol γ. Moreover HIV-1 reverse transcriptase mutants 
derived from zidovudine-resitant viruses harbor changes in aminoacid residues outside the 
active site and the drug resistance conferred by these mutations could be due to subtle 
structural changes in Pol γ (Lim et al., 2003).  
Additional effects of NRTI on mtDNA synthesis have also been suggested. Therefore, given 
that conversion of the monophosphate to the triphosphate form of NRTI inside the 
mitochondria is rather inefficient, it is possible that the monophosphorylated forms can 
accumulate within the mitochondrial matrix reaching extremely high (mM) levels which 
could have unspecific inhibitory effects on mtDNA synthesis, such as decreased mtDNA 
replication fidelity induced by the inhibition of the exonuclease function of Pol-γ, and 
inhibition of mtDNA replication, mediated by the reduction of thymidine phosphorylation, 
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a necessary substrate for DNA synthesis (Walker et al., 2003). In vivo millimolar 
accumulation has been shown for the phosphorylated form of zidovudine (Frick et al., 1988). 
Moreover, interactions with host proteins during the process of activation of NRTI inside 
the cell, allow additional mechanisms for mitochondrial toxicity of these drugs. 
4.1 Pol-γ independent mitochondrial action of NRTI 
HAART has dramatically reduced AIDS-related morbidity and mortality and has converted 
HIV-infection into chronic rather than a mortal disease (in the pre-HAART era a HIV-
infected individual was expected to survive only 7 years). However, the adverse reactions 
associated with the long-term use of this therapy (rash and hypersensibility reactions, 
hepatotoxicity, metabolic disturbances including lipodystrophy, hyperlactatemia, and CNS 
toxic effects) have become a major concern. As a result, research efforts are now focused on 
understanding the cellular mechanisms underlying these effects. Most of NRTI-induced side 
effects have been attributed to their mitotoxic potential which has mainly been believed to 
originate from the inhibitory action of these drugs on Pol γ. However, other mitochondrial 
mechanisms and targets responsible for NRTI-induced mitotoxicity have also been 
suggested. There is evidence of NRTI-induced mitochondrial dysfunction unrelated to 
mtDNA depletion. Zidovudine has been shown to inhibit thymidine phopshorylation, 
ADP/ATP translocase and adenylate kinase, to provoke a decrease in cytochrome c oxidase 
(Complex IV) expression, and to enhance oxidative stress (Maagaard & Kvale, 2009). In vivo 
studies have demonstrated that treatment with this drug leads to a disrupted cardiac 
mitochondrial ultrastructure and a diminished expression of mitochondrial cytochrome b 
mRNA, as well as induction of oxidative stress in heart mtDNA (Sardao et al., 2008). In 
addition, in cultured rat hepatocytes, stavudine, but not zidovudine or zalcitabine, impairs 
fatty acid oxidation in the absence of mtDNA depletion (Igoudjil et al., 2008). Moreover, 
mitochondrial import of nucleoside drugs may also be related to their toxicity in this 
organelle. Some of the nucleoside channels have been shown to transport stavudine, 
zalcitabine, zidovudine and didanosine (Yamamoto et al., 2007; Baldwin et al., 2005) and 
nucleoside drugs are also the subject of several other transporters, including organic cation 
and anion transporters and multi-drug-resistant proteins with potential implication in 
toxicity (Leung & Tse, 2007). Recently, mitochondrial bioenergetics has been directly linked 
to NRTI-induced mitotoxicity, independently of mtDNA replication. In vitro exposure to 
zidovudine has revealed a direct interaction with cellular bioenergetics by impairing 
mitochondrial respiration through inhibition of Complex I of the ETC (Lund & Wallace, 
2008).  
Hepatotoxicity has emerged as one of the most common adverse events associated with 
HAART and constitutes a major problem in the management of HIV-patients. In certain 
clinical trials, up to 10% of patients receiving cART exhibited a severely increased liver 
enzymes level which is a major cause of therapy discontinuation (Jain, 2007). The 
implication of mitochondria in these events and particularly the drug-induced 
mitochondrial effects that occur independently of Pol γ is still not clear. We employed a 
human hepatoma cell line, Hep3B (ATCC HB-8064) to assess the potential direct and Pol γ− 
independent involvement of mitochondria in hepatic side effects. Preliminary studies were 
performed in which cells were treated with NRTI (Sequoia Research Products) at 
therapeutic concentrations during a short period of time in order to avoid any effects due to 
a decrease in mtDNA content. Subsequently, several parameters of mitochondrial function 
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including mitochondrial respiration, generation of ATP and mitochondrial ROS production 
were determined. Electrochemical measurement of oxygen (O2) consumption was 
performed using a Clark-type O2 electrode (Rank Brothers, Bottisham, UK). Cells (3-5x106) 
were placed in a gas-tight chamber containing 1mL respiration buffer (Hank’s balanced salt 
solution, HBSS) and agitated at 37ºC. Measurements were recorded using the Duo.18 data 
acquisition device (WPI, Stevenage, UK), immediately after addition of the drugs. The 
adenosine triphosphate (ATP) concentration (nmol/mg protein) was determined using 
Bioluminescence Assay Kit HSII (Roche, Mannheim, Germany) and a Fluoroskan microplate 
reader (Thermo Labsystems, Thermo Scientific, Rockford, IL). For these measurements, cells 
were incubated for 1h with the NRTI under study. Protein concentrations were determined 
with the BCA protein assay kit. ROS production was analyzed in cells seeded in a black 96-
well plate. The fluorescent probe DCFH-DA (2´,7´-dichlorodihydrofluorescein diacetate, 2.5 
μM) was added for 30 minutes, cells were washed with HBSS before addition of  the NRTI 
drug and fluorescence was detected at 5-minute intervals over a 1h period using a 
Fluoroskan. Rotenone (100 μM) or exogenous hydrogen peroxide (H2O2, 100 μM) were used 
as a positive control. We observed that abacavir but not lamivudine significantly reduced 
mitochondrial respiration and ATP production (Fig.4). However no significant changes 
were detected regarding ROS production with either of the drugs (results not shown) (Blas-
Garcia, 2010). Other preliminary studies conducted in our laboratory have revealed that 
clinically relevant concentrations of another NRTI, didanosine, also lead to alterations in the 
mitochondrial function of Hep3B cells, detected as decreased O2 consumption and ATP 
generation, but in the absence of an increase in ROS production (unpublished data).  
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A                                                                                  B 
Fig. 4. Acute and Pol γ-independent effect of NRTI drugs (lamivudine and abacavir) on 
mitochondrial function in Hep3B cells. A) Rate of mitochondrial O2 consumption 
determined in a Clark-type O2 electrode. 10μM of lamivudine or abacavir were added to the 
chamber immediately after addition of the cell suspension. B) Intracellular ATP 
concentration studied with a bioluminescence assay in cells treated with 10μM of 
lamivudine or abacavir for 1h. Data are mean±SEM of 5-6 experiments and are shown as % 
of the control value (i.e. the value obtained in untreated cells, considered to be 100%). 
Statistical analysis was performed using the Student´s t-test, *p<0.05, vs Vehicle (Veh)-
treatment. 
* *
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These preliminary data lead to several important observations: i) some NRTI, at their 
clinically employed concentrations, have the potential to directly inhibit the mitochondrial 
oxidative phosphorylation process, and this occurs in a drug-specific manner; ii) further 
studies need to be carried out with the aim of analyzing whether these effects are transient 
or accumulate over time, particularly regarding ROS accumulation which does not seem to 
be acutely affected. However prolonged and/or more severe impairment of mitochondrial 
respiration can lead to a progressive increase in ROS generation and the subsequent 
appearance of oxidative stress; iii) the pathophysiological relevance of the mitochondrial 
effects elicited by NRTI is unclear and awaits the findings of more detailed studies. 
4.2 Factors influencing NRTI-induced mitotoxicity 
Several general factors directly influence NRTI-induced mitochondrial toxicities, both 
related and un-related to mtDNA depletion: i) the subcellular abundance of NRTI, as there 
is a concentration threshold beyond which these compounds compete with natural moieties; 
ii) the ability of cellular nucleoside kinases to create nucleoside triphosphate, which is 
responsible for mtDNA toxicity, and the interaction of nucleoside analogues with the 
resident proteins during the process of their activation; iii) the existence of a functional 
threshold as most cells contain a substantial number of mitochondria and therefore, 
manifestations of cellular injury appear only when a substantial number of malfunctional 
mitochondria is reached; and iv) the “mtDNA threshold effect” in relation with tissue 
specificity of OxPhos dependence. The majority of cells have a surplus of mtDNA copies 
and can withstand significant mtDNA depletion before mitochondrial dysfunction occurs 
(60-80% of basal levels). In the case of mutations, the threshold varies from 60% for large 
scale mtDNA deletions to 90% in tRNA point mutations. Nevertheless, the relationship 
between mtDNA content and NRTI-induced adverse events is unclear. Until recently, 
quantification of mtDNA in peripheral blood mononuclear cells (PBMC) was employed as a 
marker of mitochondrial toxicity in HIV patients. However, the accuracy of this 
measurement regarding toxicity is controversial since several studies have failed to report a 
decrease in the mtDNA content of PBMC or fat tissue in patients experiencing adverse 
events such as lipoatrophy (Maagaard & Kvale, 2009). Finally, v) recent advances in 
pharmacogenomics suggest a link between specific genetic polymorphisms and NRTI 
toxicity; for instance, R964C (Yamanaka et al., 2007) and E1143G polymorphisms (Chiappini 
et al., 2009) have been associated with an increased stavudine-induced mitotoxicity whereas 
mitochondrial haplogroup T has been related to increased peripheral neuropathy in 
treatment with stavudine and didanosine (Hulgan et al., 2005). 
5. Conclusion 
Mitochondria contain their own DNA which encodes 13 proteins which are involved in the 
mitochondrial ETC. The replication of mtDNA is performed by Pol γ, the only mitochondrial 
DNA polymerase, which consists of a catalytic subunit and a dimeric form of an accessory 
subunit p55, and operates in conjunction with two replication factors, SSB and Twinkle. A 
decreased amount of mtDNA, often due to mutations in POLG, is a hallmark of 
mitochondrial depletion syndrome, a heterogeneous group of several severe and usually 
deadly inherited disorders. Mitochondrial DNA depletion and, consequently, mitochondrial 
dysfunction are also considered to be the basis of the side effects induced by a class of drugs 
known as nucleoside analogue reverse transcriptase inhibitors. These drugs are the 
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cornerstone of the current therapeutic approach employed for treatment of HIV infection. It 
is believed that the adverse events related to NRTI-containing treatments are mainly due to 
the mitochondrial toxicity that arises as a result of the inhibitory effect of these drugs on Pol 
γ. However, Pol γ-independent mitochondrial targets and mechanisms of NRTI-induced 
toxicity have also been suggested. Using a human hepatic cell line, our group has recently 
provided in vitro evidence of a direct inhibitory effect on mitochondrial respiration and ATP 
production induced by an acute exposure to certain NRTI such as abacavir and didanosine. 
No such changes were observed with lamivudine, thus indicating a drug- rather than a 
class-specific effect. A detailed analysis of these effects is paramount to a better 
understanding of NRTI-related adverse events. This is of particular clinical relevance given 
the existence of NRTI that do not exhibit a strong Pol γ -inhibitory action.  
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